441 related articles for article (PubMed ID: 11504822)
1. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
Webb MS; Logan P; Kanter PM; St-Onge G; Gelmon K; Harasym T; Mayer LD; Bally MB
Cancer Chemother Pharmacol; 1998; 42(6):461-70. PubMed ID: 9788572
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
4. Are PEGylated liposomes better than conventional liposomes? A special case for vincristine.
Wang X; Song Y; Su Y; Tian Q; Li B; Quan J; Deng Y
Drug Deliv; 2016 May; 23(4):1092-100. PubMed ID: 26024386
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
6. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
Webb MS; Harasym TO; Masin D; Bally MB; Mayer LD
Br J Cancer; 1995 Oct; 72(4):896-904. PubMed ID: 7547237
[TBL] [Abstract][Full Text] [Related]
7. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
[TBL] [Abstract][Full Text] [Related]
9. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs.
Zhong J; Mao W; Shi R; Jiang P; Wang Q; Zhu R; Wang T; Ma Y
Cancer Chemother Pharmacol; 2014 Mar; 73(3):459-66. PubMed ID: 24362508
[TBL] [Abstract][Full Text] [Related]
11. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin.
Johnston MJ; Semple SC; Klimuk SK; Ansell S; Maurer N; Cullis PR
Biochim Biophys Acta; 2007 May; 1768(5):1121-7. PubMed ID: 17321495
[TBL] [Abstract][Full Text] [Related]
13. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.
Webb MS; Saxon D; Wong FM; Lim HJ; Wang Z; Bally MB; Choi LS; Cullis PR; Mayer LD
Biochim Biophys Acta; 1998 Jul; 1372(2):272-82. PubMed ID: 9675310
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
16. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.
Mayer LD; Masin D; Nayar R; Boman NL; Bally MB
Br J Cancer; 1995 Mar; 71(3):482-8. PubMed ID: 7880728
[TBL] [Abstract][Full Text] [Related]
18. In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors.
Leonetti C; Scarsella M; Semple SC; Molinari A; D'Angelo C; Stoppacciaro A; Biroccio A; Zupi G
Int J Cancer; 2004 Jul; 110(5):767-74. PubMed ID: 15146568
[TBL] [Abstract][Full Text] [Related]
19. Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors.
Shah VM; Nguyen DX; Alfatease A; Bracha S; Alani AW
J Control Release; 2017 May; 253():37-45. PubMed ID: 28302582
[TBL] [Abstract][Full Text] [Related]
20. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs.
Kanter PM; Klaich GM; Bullard GA; King JM; Bally MB; Mayer LD
Anticancer Drugs; 1994 Oct; 5(5):579-90. PubMed ID: 7858291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
